OS Therapies Incorporated, a clinical-stage biopharmaceutical company focused on developing treatments for Osteosarcoma and other solid tumors, reported significant financial developments in its recent 10-K filing for the fiscal year ending December 31, 2025. The company recorded total operating expenses of approximately $28.7 million, a substantial increase from $6.8 million in the previous year. This rise was primarily driven by heightened research and development costs, which surged to $16.4 million from $2.8 million, reflecting ongoing efforts to advance its lead product candidate, OST-HER2, through clinical trials and regulatory preparations.
The company reported a net loss of approximately $28.8 million for 2025, compared to a net loss of $8.9 million in 2024. As of December 31, 2025, OS Therapies had cash and cash equivalents of approximately $269,830, a significant decrease from $5.5 million at the end of 2024. The company has primarily funded its operations through public and private offerings, raising approximately $41.1 million since its inception. However, the current cash balance is insufficient to fund ongoing operations, raising concerns about the company's ability to continue as a going concern without additional capital.
In terms of strategic developments, OS Therapies completed the acquisition of HER2-related assets from Ayala Pharmaceuticals in April 2025, which included two investigational new drug applications for non-small cell lung cancer and prostate cancer. The acquisition was valued at $8 million, paid through a combination of cash and stock. The company also engaged in several financing activities, including a PIPE financing that generated approximately $7.1 million and a bridge financing that raised $2 million in early 2026. These funds are intended to support regulatory efforts for OST-HER2 and advance the company's research and development programs.
Operationally, OS Therapies has made progress in its clinical trials, achieving full enrollment of 41 patients in its Phase IIb trial for OST-HER2 by October 2023. The trial met its primary endpoint with statistical significance, showing a two-year overall survival rate of 75% among treated patients compared to 40% in historical controls. The company plans to submit a Biologics License Application (BLA) to the FDA in 2026 and anticipates initiating confirmatory studies in support of conditional approval pathways. The company also aims to explore the potential of OST-HER2 in treating other solid tumors, including breast and lung cancers.
Looking ahead, OS Therapies faces challenges related to its financial position and the need for additional capital to sustain its operations and development efforts. The company has expressed intentions to pursue equity and debt financing to support its growth strategy. However, uncertainties surrounding regulatory approvals and market conditions may impact its ability to generate revenue and achieve profitability in the future. The company remains focused on its mission to address the unmet medical needs in the treatment of Osteosarcoma and other solid tumors, while navigating the complexities of the biopharmaceutical landscape.
About OS Therapies Inc
OS Therapies Inc. is a biopharmaceutical company developing innovative immunotherapies and targeted treatments for osteosarcoma and other solid tumors. Its pipeline includes OST-HER2, an immunotherapy for rare cancers, and OST-tADC, a tunable antibody-drug conjugate platform targeting multiple cancers. The company focuses on clinical-stage development, leveraging proprietary technology, strategic collaborations, and regulatory designations to address unmet medical needs in oncology.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.